PipelineReview.com - Target Pipelines

Show Cart

Target Pipelines

Results 41 - 50 of 80

Jul 2018 LAG-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIM-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIGIT Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 B7-H3 Immune Checkpoint Inhibitors - Target Pipeline List 07/2018

Jul 2018 GITR Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 OX40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 CD27 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 ICOS Immune Checkpoint Activators – Target Pipeline List 07/2018

Jun 2018 Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

(Discount: 40.00%)

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing